40 results about "Targeted liposomes" patented technology

The application discloses a method for modifying phospholipids and application thereof in preparation of liver-targeted liposomes, relates to the field of drug delivery, and first utilizes cholate and mannose to modify phospholipid molecules DSPE-PEG 2000 respectively 2000 Two raw materials DSPE-PEG 2000 -CA and DSPE-PEG 2000 -MAN for synthesizing liposomes are synthesized, and then cholesterols, DSPC and DC-cholesterols are added in a certain proportion to obtain liposomes with liver targeting property, which have high cell safety and liver cell targeting property.

Methods and compositions for the treatment of viral infections, such as HIV infection, are disclosed herein. In certain embodiments, a molecular conjugate comprising a viral capture domain and an immunostimulant molecule is provided.

The application discloses a liver-targeting lipid carrier as well as a preparation method and application thereof, relates to the field of drug delivery, and utilizes cholate and mannose to respectively modify a phospholipid molecule DSPE-PEG 2000 After two raw materials DSPE-PEG-CA and DSPE-PEG-MAN composed of synthetic liposomes are obtained, the liver-targeting lipid carrier is obtained according to a certain proportion of cholesterol, DSPC, DC-cholesterol and the like, and the liposome has high cell safety and liver targeting.

This invention relates to the fields of pharmaceuticals and nanomedicine, specifically disclosing the preparation of a dual-targeting liposome drug delivery system and its application in stroke. The dual-targeting liposome drug delivery system comprises neutrophils, artemisinin, edaravone, and liposomes. The liposomes co-load artemisinin and edaravone, and their surfaces are modified with sialic acid derivatives and phosphatidylserine to form liposome nanomedicines. The neutrophils act as carriers, transporting the drug across the brain border (BBB) ​​and targeting it to the ischemic brain region. This dual-targeting strategy achieves precise two-stage drug delivery to the ischemic brain region. This delivery system can inhibit NLRP3 inflammasome activation, reduce pyroptosis, and promote microglial polarization towards the M2 anti-inflammatory phenotype, thereby effectively treating cerebral ischemia-reperfusion injury or ischemic stroke.

The invention discloses a targeted liposome and application thereof, a targeted liposome preparation and a preparation method and application thereof, and relates to the technical field of biology.The targeted liposome is prepared from, by mole, 50%-55% of distearoyl phosphatidylcholine, 30%-35% of cholesterol, 4%-6% of phosphatidyl glycerol, 7%-8% of DSPE-PEG2000 and 0.3%-0.6% of DSPE-PEG2000-targeted peptide, and the targeting peptide in the DSPE-PEG2000-targeting peptide comprises at least one of an ANG2 peptide, a Tf peptide and an ApoE peptide. According to the application, the targeted liposome crosses the blood brain barrier, and efficient release of drug molecules aiming at brain glioma cells is realized.

The invention relates to the technical field of biological medicine, and particularly discloses a lipidosome targeting SELENOP + macrophages, a preparation method of the lipidosome and application of the lipidosome in lung squamous cell carcinoma treatment. According to the lipidosome, an SELENOP antibody is used as a targeted modification molecule, si-SELENOP and s-ABCA1 / G1 are loaded, and accurate delivery of siRNA in target cells is achieved through specific binding of the antibody and a SELENOP receptor on the surface of a SELENOP + macrophage. The targeting liposome prepared by the invention can specifically inhibit cholesterol efflux pathways of SELENOP + macrophages, reverse tumor phenotypic polarization, remodel a tumor immune microenvironment and recover anti-tumor activity of immune cells such as CD8 + T cells, NK cells and the like. When the liposome is independently used or combined with a PD-1 antibody, the growth and metastasis of the lung squamous cell carcinoma can be remarkably inhibited, the treatment effect is improved, a brand new metabolism-immunity synergistic targeted treatment strategy is provided for the lung squamous cell carcinoma, and the liposome has a good clinical application prospect.

A natural immune agonist complex, consisting of an immune agonist and a targeted liposome, where the immune agonist is M(cGAMP)Ln. The targeted liposome is formed by a nanobody targeting a tumor microenvironment, a cell membrane-targeted penetrating peptide, or a blood-brain barrier-targeted penetrating peptide with a liposome through chemical bonding. This application further provides a preparation and application of the natural immune agonist complex.

The present application relates to the technical field of biological medicine, in particular to a functionalized targeted liposome and application thereof, comprising: lipids and a targeting ligand; wherein the targeting ligand can specifically bind to a TREM2 receptor. The liposome of the present application can specifically bind to the TREM2 receptor by means of the targeting ligand, realize precise targeting of cells containing the TREM2 receptor on the surface, ensure direct action on target cells, and further improve the precision of delivered substances. The liposome has targeting property, high stability, small side effects, and can be applied to the development of drug carriers, pharmaceutical compositions, etc., and has a wide application prospect. For example, the liposome of the present application is dynamically connected with a hydrogel molecule by a borate ester bond to prepare a hydrogel pharmaceutical composition containing the functionalized targeted liposome of the present application. The hydrogel pharmaceutical composition can release the liposome of the present application according to the change of pH and ROS in the surrounding environment in response to an inflammatory environment, and target cells containing the TREM2 receptor on the surface, i.e. microglial cells (having the TREM2 receptor on the surface), by virtue of the targeting ligand exposed on the surface, and regulate the polarization state of the cells, inhibit the polarization of the cells to the pro-inflammatory M1 type, and promote the polarization of the cells to the anti-inflammatory M2 type, thereby improving the local microenvironment of the spinal cord injury site and promoting nerve regeneration.

The present application relates to an exosome fusion liver-targeting liposome drug delivery system and its preparation method and application, and belongs to the field of polymer materials and pharmaceutical preparations. The present application discloses an exosome fusion liver-targeting liposome drug delivery system, which uses high-concentration PEG 8000 and Nycodenz in combination to synergistically improve the exosome and liposome fusion efficiency, form biomimetic vesicles with uniform size and high drug loading. The exosome not only can play the characteristics of anti-inflammatory and antioxidant, but also plays a role in resisting harsh gastrointestinal environment and crossing biological barriers. In addition, the liposome is modified by cholic acid derivative by using EDC / NHS mediated amidation reaction, which realizes precise targeting of liver and sufficient accumulation in liver. The above-mentioned effects synergistically realize the treatment of type II diabetes and non-alcoholic fatty liver disease.

The invention discloses a multifunctional medical coupling agent and a preparation method and application thereof, and belongs to the field of medical materials.The coupling agent comprises (1) an electric insulation gel matrix formed by perfluoropolyether oil and fluorinated gel; (2) temperature-responsive nanoparticles which are uniformly dispersed in the gel matrix and have surfaces subjected to hydrophobic modification, wherein the temperature-responsive nanoparticles contain rare earth ions Y < 3 + >, Yb < 3 + > and Er < 3 + >; and (3) fluorinated targeted liposome which is uniformly dispersed in the gel matrix and is modified with sulfhydrylated RGD peptide on the surface, wherein a therapeutic drug is encapsulated in the fluorinated targeted liposome. Wherein the perfluoropolyether oil ensures the electrical insulation safety; the temperature response type nanoparticles emit fluorescence signals, and the fluorescence signals can be inverted into temperature values; the sulfhydrylated RGD peptide recognizes and is combined with tumor angiointegrin alpha v beta 3, so that active targeting can be realized. The multifunctional medical coupling agent disclosed by the invention has multiple functions of electrical insulation safety guarantee, temperature monitoring, targeted drug delivery and the like, and meets the requirements of complex medical scenes.

The invention particularly relates to a cabozantinib and osimertinib co-loaded targeting liposome and application thereof in overcoming EGFR-TKI drug resistance, and belongs to the technical field of biological medicine. The co-drug-loaded targeting liposome disclosed by the invention is coated with osimertinib and cabozantinib at the same time, and a GE11 peptide targeting ligand is connected to a membrane material of the co-drug-loaded targeting liposome; wherein the mass ratio of osimertinib to cabozantinib is 1: (0.5-2), preferably 1: 1; the membrane material comprises hydrogenated soybean phosphatidylcholine, cholesterol and DSPE-PEG2000, and the mass ratio of the hydrogenated soybean phosphatidylcholine to the cholesterol to the DSPE-PEG2000 is (2.5-3.5): 1: 1. According to the co-drug-loading targeting liposome disclosed by the invention, a drug can be synergistically delivered to a tumor site through active targeting mediated by GE11 peptide, an EGFR main pathway and key drug-resistant bypasses such as MET are efficiently inhibited, and the co-drug-loading targeting liposome shows a remarkable synergistic interaction effect in the aspect of reversing acquired drug resistance of osimertinib.

The invention belongs to the technical field of drug carriers, and particularly relates to tumor-targeted luteoloside liposome loaded paclitaxel and a preparation method thereof. According to the tumor targeted liposome, luteoloside and soya bean lecithin are used as membrane materials, a blank liposome (C-Blank) is prepared through a membrane hydration method and a high-pressure homogenization method, and a hydrophobic drug paclitaxel (PTX) is loaded to obtain a drug-loaded liposome (C-PTX). Wherein the luteoloside can significantly enhance the mechanical strength and thermodynamic stability of the lipid bilayer, and also can realize active tumor targeting through a glucose transporter GLUT1 mediated endocytosis pathway, and meanwhile, PTX is efficiently entrapped in a liposome hydrophobic core. The C-PTX liposome prepared by the invention is small in particle size, relatively good in endocytosis capability, good in blood long-circulation effect and drug delivery capability, good in stability and dispersity, high in drug encapsulation efficiency and beneficial to effective delivery and release of drugs. The oral bioavailability of PTX is improved, and C-PTX has an obvious inhibition effect on lung cancer cells. The drug loading system effectively overcomes the defects that a traditional paclitaxel preparation is poor in water solubility, large in system toxicity, insufficient in targeting performance and the like, the highly-uniform dispersion state and long-term storage stability of the drug loading system lay a foundation for industrial production, and the drug loading system shows important clinical application potential in the fields of precision medicine and transformation medicine.

The application discloses a liposome construction recommendation method and device based on drug molecular structure, and the recommendation method is characterized in that, after receiving the molecular information of a target drug input by a user, firstly, the molecular information is subjected to data preprocessing; then, a pre-trained liposome recommendation model is used to make a recommendation based on standard molecular characteristic data; finally, the construction parameters are optimized based on the target liposome construction type, so that the target liposome construction parameters are obtained. The pre-trained neural network model is used to make a recommendation on the construction type of the liposome based on the drug molecular information, and the construction parameters of the liposome are optimized to obtain the optimal liposome construction parameters. The drug molecular structure characteristics are directly associated with the liposome construction scheme, and the efficiency and accuracy of the liposome construction are improved.

The invention discloses an engineered exosome for targeted improvement of an ovarian function as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The engineered exosome is prepared by performing membrane fusion on an exosome from human umbilical cord mesenchymal stem cells overexpressing VEGFA (vascular endothelial growth factor A) genes and an FSH (follicle stimulating hormone) beta subunit derived peptide modified liposome. The exosome has the functions of promoting angiogenesis and resisting apoptosis of VEGFA (vascular endothelial growth factor A) and the ovarian targeting capability of the FSH beta peptide fragment, can accurately act on ovarian granular cells, and effectively improves the ovarian microenvironment and follicle development. The preparation method comprises the following steps: constructing VEGFA overexpression engineering cells, extracting exosomes, synthesizing targeted lipidosome, performing ultrasonic induction fusion and the like. The engineered exosome provided by the invention has the advantages of strong targeting, definite curative effect, high uniformity, good safety and the like, and provides a new strategy for cell-free treatment of ovarian function decline and related reproductive disorders.

The invention discloses a preparation method and application of glucose transporter 1 targeting brucea javanica fatty acid prodrug liposome, and belongs to the technical field of pharmaceutical preparations. Specifically, the invention relates to a targeting material based on glucose transporter 1 (GLUT1), a tumor sensitive bond bridged brucea javanica-fatty acid prodrug, construction of an active targeting liposome containing the prodrug, and application of the active targeting liposome in preparation of antitumor drugs. The anti-liver cancer effect of the liposome is investigated. Results show that the lipidosome designed by the invention can realize targeted drug delivery to tumor tissues, the anti-tumor efficacy of the brucea javanica terpene drug is remarkably improved, the biosafety is high, and the toxicity is reduced by two times compared with that of the original drug brucea javanica bitter alcohol. The tolerance dose of the chemotherapeutic drug is expected to be increased, the anti-tumor effect of the chemotherapeutic drug is improved, and a new direction and a new thought are provided for the delivery of the chemotherapeutic drug.

The application provides a liposome synthesis method and a synthesis device, and the method comprises the following steps: two liquids of an organic phase and an aqueous phase are respectively introduced into two sample introduction channels of a Y-shaped flow channel; the Y-shaped flow channel comprises the two sample introduction channels and a synthesis channel which is in communication with the converging position of the two sample introduction channels; a special ultrasonic device in the shape of a regular pentagon arranged at the bottom of the synthesis channel is driven to work, and at least through the micro-vortices generated in the liquid in the synthesis channel and distributed at the positions of the edges of the regular pentagon during the working of the special ultrasonic device, the two liquids in the synthesis channel are mixed to generate target liposomes. Through the cooperative design of the micro-flow channel structure and the special ultrasonic device, the synthesis efficiency of the liposomes can be significantly improved, and the average particle size and uniformity of the product in the synthesis process of the liposomes are optimized.

The invention discloses a cabozantinib liver-targeting lipid nanoparticle injection as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The cabozantinib injection is prepared from the following components in percentage by mass: 0.8 to 1.5 percent of cabozantinib, 2.5 to 4.0 percent of DSPE-PEG2000-galactose, 35.0 to 42.0 percent of dipalmitoyl phosphatidylcholine, 6.0 to 8.0 percent of sitosterol, 3.0 to 5.0 percent of composite freeze-drying protective additive and the balance of citric acid-sodium citrate buffer solution with the pH value of 4.0, and the composite freeze-drying protective additive is a mixture of hydroxypropyl-cyclodextrin and mannitol in a mass ratio of 2 to 1. The preparation provided by the invention reduces systemic toxicity, significantly improves the drug concentration of liver and tumor parts, has better tumor inhibition effect than clinical positive drug adriamycin, is suitable for treatment of liver cancer and hepatic metastatic tumor, and has a relatively high application prospect.

The invention relates to an application of TLR < 4 > siRNA (TLR < 4 > siRNA (at) LNP-CSA-BP) coated with TLR < 4 > siRNA (TLR < 4 > siRNA) connected with placental Chondroitin sulfate A binding peptide (Placental Chondroitin sulfate A binding peptide, CSA-BP) injected in a maternal pregnancy period, in improvement of pregnancy complications and prevention of progeny neurodevelopment disorder diseases, in particular to an application of TLR < 4 > siRNA coated with LNP-CSA-BP coated with TLR < 4 > siRNA coated with LNP-CSA-BP. According to the invention, TLR4siRNA (at) LNP-CSA-BP is used for carrying out caudal vein injection on a pregnant mouse, so that a placenta and fetal brain inflammation microenvironment (induced by toxoplasma gondii STAg) maternal immune activation can be inhibited. Behavior experiments further prove that under a maternal immune activation model, TLR4siRNA (at) LNP-CSA-BP caudal vein injection pregnant mice can significantly improve phenotypes of neurodevelopmental disorder diseases of filial generation mice, such as core symptoms (social ability and repeated engraving behaviors) of autism behaviors, and the promising transformation prospect is proved.

This invention relates to an immunoliposome containing tebuconazole, its preparation method, and its application in anti-breast cancer treatment. The tebuconazole immunoliposome is composed of tebuconazole coated with phospholipids and cholesterol, and modified with trastuzumab. The preparation method of the tebuconazole immunoliposome of this invention is simple and exhibits excellent anti-tumor effects. The novel tebuconazole immunoliposome can overcome the drawback of tebuconazole's non-selectivity for tumor cells, thus enhancing its anti-tumor efficacy. Furthermore, the actively targeted immunoliposome with trastuzumab as a target exhibits significant targeting in vivo, and its anti-tumor effect is significantly different from that of non-targeted liposomes. This invention provides a new avenue for the anti-tumor application of tebuconazole and is of great significance for advancing the clinical application of tebuconazole.

The present application relates to ligands targeted to epidermal growth factor receptor (EGFR) and compositions for use in treating tumors. Specifically, a ligand targeted to EGFR is disclosed. The ligand comprises a heavy chain variable domain and a light chain variable domain. The ligand may be selected from the group consisting of a single chain variable fragment, a fusion protein, a monoclonal antibody, and an antigen-binding fragment thereof. The ligand may be conjugated to a liposome or a nanoparticle that encapsulates at least one chemotherapeutic agent to form a ligand-targeted liposomal or nanoparticle drug. Also disclosed are conjugates and formulations for use in treating tumors such as squamous cell carcinoma of head and neck. A method for making a ligand-targeted liposomal drug is also disclosed. The drug may be a chemotherapeutic agent selected from the group consisting of doxorubicine and vinorelbine.

The invention provides a hair follicle targeting liposome, a preparation method and application of the liposome in drugs and cosmetics, and relates to the technical field of biological medicines.The liposome is composed of, by weight, 20-80 parts of lecithin and 5-15 parts of notoginsenoside, the lecithin is used as a framework, the surface of the liposome presents negative Zeta potential, and the liposome is prepared into the hair follicle targeting liposome. The electrostatic repulsion effect between the particles and the skin cuticle is enhanced, non-specific adsorption is reduced, migration and retention of the particles along the hair follicle path are facilitated, and the skin retention property and the hair follicle targeting property are improved; meanwhile, notoginsenoside is used as a membrane material, inflammation caused by emasculation is reduced, hair follicle generation is promoted, collagen deposition is improved, the notoginsenoside and lecithin have a synergistic effect, and the characteristics of membrane forming property, high encapsulation efficiency, hair follicle targeting property and retention property are achieved. The technical problems of poor hair follicle targeting property and retention property caused by low liposome encapsulation efficiency and single membrane material function in the prior art are solved.

The invention discloses a pH response type double-drug targeting liposome, a preparation method thereof and application of the pH response type double-drug targeting liposome in pancreatic cancer treatment, a functional structure unit DSPE-hyd-PEG2000-RGD is obtained by organically combining a pH sensitive hydrazone bond with a targeting peptide, so that a liposome interface structure with stable circularity and environmental responsiveness is constructed; meanwhile, an anti-pancreatic cancer drug with a synergistic immune activation and metabolism regulation effect is entrapped in the lipidosome, a targeting-triggering-drug release integrated mechanism is formed, the lipidosome can realize a dual anti-tumor mechanism of immune activation and metabolism remodeling, the efficiency of accumulation of the drug at a tumor site and delivery in cells is effectively improved, and the anti-pancreatic cancer effect is improved. The treatment safety is improved, the systemic toxicity is reduced, and good clinical transformation potential is achieved; the preparation method is simple, convenient and high in repeatability, and the prepared liposome is good in stability and has good industrialization potential.

The application discloses a polypeptide specifically combined with human lung cancer cells and application thereof, and the amino acid sequence of the disclosed polypeptide is FGWQTNHNTSFM.The polypeptide of the application has better specificity and sensitivity in combination with human lung adenocarcinoma and tissues.Furthermore, the polypeptide is used to prepare lung cancer targeted doxorubicin (DOX) liposomes, and experiments in vitro prove that the targeted liposome drug has better lung cancer cell killing effect than common DOX.The polypeptide sequence has important use value and prospect in early image diagnosis of lung cancer and research and development of targeted anti-tumor drugs.

The invention provides selenium nanoparticle hydrogel loaded with collagen targeted liposome as well as a preparation method and application of the selenium nanoparticle hydrogel, and belongs to the technical field of biological medicines. According to the invention, firstly, H-151-encapsulated lipidosome is synthesized, and the surface of the lipidosome is modified with a collagen specific binding peptide (LHERHLNNN), so that the H-151-loaded lipidosome has tendon targeting property and can be accumulated in quantity around young TDSCs, and the administration efficiency is enhanced. On the other hand, hyaluronic acid grafted with phenylboronic acid is used as a capping agent to synthesize selenium nanoparticles (HPSe), then the selenium nanoparticles react with polyvinyl alcohol to form gel (PVA / HASe), ROS responsiveness and injectability are achieved, TDSCs targeting liposome encapsulating H-151 is loaded, and a hydrogel composite system is formed. According to the hydrogel composite system, through the synergistic effect of anti-aging, anti-inflammatory and immune regulation, the homeostasis of senescent tendons is maintained, finally, repair of tendinopathy is promoted, and an effective treatment strategy is provided for repair of senescent tendinopathy.

The invention discloses a preparation method of a nano preparation for releasing hydrogen sulfide gas in an acidic response manner in a targeted bone resorption area. The preparation method comprises the following steps: S1, preparing polypeptide phospholipid DSPE-PEG-ASP8 with bone resorption area targeting property; s2, synthesizing a prodrug JK-1; s3, preparing a bone targeting liposome loaded with JK-1; the nano preparation is prepared by a method of entrapping a prodrug JK-1 capable of releasing HS under an acidic condition in a liposome with a bone resorption region targeting characteristic, so that accurate release of HS in a bone resorption microenvironment can be realized, and the problems of poor targeting property, uncontrollable release, low loading efficiency and the like in a traditional hydrogen sulfide delivery system are solved; the treatment efficiency is improved; and systemic side effects are reduced.

The invention discloses an active oxygen (ROS) response type targeted liposome double-drug co-delivery system for treating pulmonary fibrosis as well as a preparation method and application thereof, and belongs to the technical field of biological medicine and nano-drug delivery. Structural phospholipid, charged phospholipid, cholesterol and a polyethylene glycol-phospholipid derivative containing a thioketal bond and cRGD peptide are used as membrane materials, GC-1 is embedded into a phospholipid bilayer through a membrane hydration-extrusion method, salvianolic acid B is encapsulated in the liposome, and the liposome with negative electricity on the surface is prepared. Negative charges on the surface of the liposome are beneficial to penetrating an airway mucus barrier and reducing alveolar macrophage removal, the modified cRGD enables the liposome to be enriched in a fibrosis focus, and the thioketal bond fractured liposome rapidly disintegrates and releases drugs in a high ROS environment in a focus area. The synergistic treatment that GC-1 promotes alveolar epithelium type II cells to be redifferentiated into type I cells and salvianolic acid B removes ROS is achieved, and therefore the pulmonary fibrosis process is efficiently reversed.

The invention relates to the technical field of encapsulation of composite liposome containing hydrogen molecules and traditional Chinese medicine active substances, in particular to a traditional Chinese medicine coating for auxiliary targeted therapy of neurodegenerative diseases and a preparation method of the traditional Chinese medicine coating, and particularly, the traditional Chinese medicine coating is used for auxiliary targeted therapy of the neurodegenerative diseases by encapsulating the composite liposome. Active extracts of traditional Chinese medicines are combined with high-concentration hydrogen molecules, and targeted liposome nano-delivery is utilized to assist in synergistically recuperating amyotrophic lateral sclerosis (ALS, gradual freezing), Alzheimer's disease and Parkinson's disease (PD).

The invention belongs to the technical field of medicines, and discloses a liposome for resisting angiogenesis and down-regulating PD-L1 protein as well as a preparation method and application of the liposome. According to the invention, the active targeting liposome which is modified by NGR and is co-loaded with axitinib and siRNAPD-L1 is prepared by a film dispersion method and a lipid co-extrusion method. The method is simple in preparation process, low in cost, good in stability and high in repeatability. On one hand, Axi / siRNAPD-L1-coated NGR-Lipo inhibits tumor microangiogenesis, reshapes a tumor vascular system, normalizes tumor vessels, inhibits tumor metastasis and improves a tumor immunosuppression microenvironment; on the other hand, PD-L1 protein on the surfaces of tumor cells is silenced, tumor immune escape is relieved, and tumor immunotherapy is enhanced. The Axi / siRNAPD-L1 coated NGR-Lipo realizes an enhanced anti-tumor effect by combining an anti-angiogenesis therapy and an immune checkpoint blocking therapy. The preparation process of the liposome is simple and rapid, is easy for large-scale and industrial production, and also has a better development prospect in the aspect of clinical application transformation.

The invention belongs to the technical field of biological medicine, and particularly relates to application of a short peptide entrapped by lung-targeted liposome and used for blocking combination of PKM2-FOXO3A in preparation of a medicine for treating stroke-related lung injury, the amino acid sequence of the short peptide is shown as SEQ ID NO.1, the SEQ ID NO.1 RKGEDREGKR and Pe (at) P-Lipo can be used for remarkably relieving MCAO mouse lung tissue pathological injury, and can be used for preparing a medicine for treating stroke-related lung injury. According to the present invention, with the application of the cerebral ischemia injury in the lung, the total reactive oxygen species (ROS) level in the lung tissue and the mitochondrial ROS level, the reduction of the ATP content can be reversed, the level of the lung tissue inflammation-related protein can be reduced, and the enrichment of PKM2, FOXO3A and TXNIP in the mitochondria can be reduced so as to alleviate the lung tissue oxidative stress and the mitochondrial injury caused by the cerebral ischemia injury, and provide the lung protection effect;